All In Biotech

Free tool

FAERS Monitor: Winlevi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213433 or its brand name (Winlevi, Clascoterone). Reports on generic versions are filed under their own applications.

Reports

1,419

Serious

75

5% of reports

Hospitalization

6

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product storage error333
  • product physical consistency issue329
  • product use complaint286
  • product dose omission issue184
  • product use issue153
  • drug ineffective146
  • therapy cessation86
  • poor quality product administered84
  • product physical issue78
  • condition aggravated76
  • product quality issue67
  • acne46
  • off label use38
  • erythema30
  • liquid product physical issue25

Reports by year received

View as table
YearReports
20214
2022500
2023210
2024422
2025269
202614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,740 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product physical consistency issueSignal329936.7848.8288,451
product use complaintSignal286274.0246.876,182
poor quality product administeredSignal84119.196.79,645
product physical issueSignal7857.546.34,264
product storage errorSignal33356.651.518,137
liquid product physical issueSignal2551.034.51,172
therapy cessationSignal8624.920.31,948
product use issueSignal15312.110.41,556
product dose omission issueSignal1849.38.11,369
acneSignal469.06.8320
product quality issueSignal677.35.8361
condition aggravatedSignal763.73.0150
erythemaSignal302.21.518
drug ineffective1461.61.438
off label use380.60.57

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.